// App-Quantinova.ai

TP1319 : Strong dose‐response on immunoglobulin markers during a phase II allergen immunotherapy study with subcutaneously administered tyrosine adsorbed modified grass allergen + MPL

Researchers

Presenter

  • Zielen S

Principal Investigators

  • Aberer W

  • Lassmann S

  • Wade A

  • Kluehr K

  • Raab J

  • Lee D

  • Ballard R

  • Jones C

  • Gunawardena K

  • Kramer MF

  • Skinner MA

  • Hingebottam T

  • De Kam P

Medical Centers

  • Department for Children and Adolescents, Frankfurt, Germany

  • Division of Hematology, Graz, Austria

  • Pulmonology and Cystic fibrosis, Saalfeld, Germany

  • Goethe University, Worthing, United Kingdom

  • Department of Dermatology, Kassel, Germany

  • Ulm University, Munich, Germany

  • Specialist in Otolaryngology, Munich, Germany

  • Allergy Therapeutics Ltd, Worthing, United Kingdom

  • Bencard Allergie Gmbh, Munich, Germany

Locations

  • Germany

  • Austria

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Immunoglobulin E

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved